new oral glp 1 agonist Orforglipron, an Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes New GLP-1 Guidelines for Type

The history of medical therapy in obesity has been frustrating: many treatments were not effective at all

Gymnema Called the "sugar destroyer," this herb reduces sugar absorption in the intestines

While lifestyle modifications such as dietary changes, increased physical activity, and behavioral therapy remain the foundation of treatment, their long-term effectiveness is often limited, especially in cases of severe obesity

Concurrently, Structure Therapeutics is advancing an APJ-targeting molecule into Phase 2 evaluation for obesity, suggesting that the target remains of clinical interest when candidate molecules are appropriately selected